1. Home
  2. GETY vs MIRM Comparison

GETY vs MIRM Comparison

Compare GETY & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GETY
  • MIRM
  • Stock Information
  • Founded
  • GETY 1995
  • MIRM 2018
  • Country
  • GETY United States
  • MIRM United States
  • Employees
  • GETY N/A
  • MIRM N/A
  • Industry
  • GETY Industrial Machinery/Components
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • GETY Industrials
  • MIRM Health Care
  • Exchange
  • GETY Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • GETY 941.4M
  • MIRM 2.0B
  • IPO Year
  • GETY N/A
  • MIRM 2019
  • Fundamental
  • Price
  • GETY $2.10
  • MIRM $42.04
  • Analyst Decision
  • GETY Buy
  • MIRM Strong Buy
  • Analyst Count
  • GETY 5
  • MIRM 11
  • Target Price
  • GETY $5.61
  • MIRM $57.00
  • AVG Volume (30 Days)
  • GETY 612.4K
  • MIRM 376.0K
  • Earning Date
  • GETY 11-07-2024
  • MIRM 02-26-2025
  • Dividend Yield
  • GETY N/A
  • MIRM N/A
  • EPS Growth
  • GETY N/A
  • MIRM N/A
  • EPS
  • GETY 0.13
  • MIRM N/A
  • Revenue
  • GETY $917,902,000.00
  • MIRM $307,028,000.00
  • Revenue This Year
  • GETY $4.33
  • MIRM $82.14
  • Revenue Next Year
  • GETY $1.96
  • MIRM $26.18
  • P/E Ratio
  • GETY $15.77
  • MIRM N/A
  • Revenue Growth
  • GETY N/A
  • MIRM 112.14
  • 52 Week Low
  • GETY $2.06
  • MIRM $23.14
  • 52 Week High
  • GETY $5.77
  • MIRM $48.89
  • Technical
  • Relative Strength Index (RSI)
  • GETY 23.62
  • MIRM 47.79
  • Support Level
  • GETY $2.06
  • MIRM $40.91
  • Resistance Level
  • GETY $2.31
  • MIRM $42.40
  • Average True Range (ATR)
  • GETY 0.13
  • MIRM 1.45
  • MACD
  • GETY -0.01
  • MIRM -0.13
  • Stochastic Oscillator
  • GETY 5.80
  • MIRM 51.04

About GETY Getty Images Holdings Inc.

Getty Images Holdings Inc is engaged in the core mission of bringing the world's creative and editorial visual content solutions to its customers to engage their audiences. the company has developed market enhancements across e-commerce, content subscriptions, user-generated content, diverse and inclusive content, and proprietary research alongside investment in its technology platform, which includes artificial intelligence and machine learning-driven search functionality and image editing and integrated APIs, to become a trusted industry leader in the visual content. Geographically the company operates in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, out of which a majority of its revenue is generated from the Americas.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: